You know I love the oncolytic virus approach!
IDOV-Immune is a promising experimental cancer therapy that uses a genetically modified vaccinia virus to target and destroy tumor cells. It works through oncolysis—replicating inside cancer cells until they burst—while simultaneously triggering an immune response by releasing tumor-specific antigens. This dual action transforms tumors into personalized vaccines, training the immune system to attack cancer elsewhere in the body. Particularly effective in resistant cancers like metastatic prostate, triple-negative breast, and colorectal cancer, IDOV-Immune may convert “cold” tumors into “hot” ones, boosting the success of immune checkpoint inhibitors.
Its precision targeting minimizes damage to healthy tissue, and it can be enhanced with additional genetic payloads.
Let's hope for the best!
Cancer at the cell level Peter Attia
Researchers discover vaccine originally created for HIV may also combat [prostate] cancer! 
